Skip to main content
  • x-twitter
  • facebook
  • youtube
  • instagram
Donate to EGFR Resisters to Continue Vital Research
Hit enter to search or ESC to close
Close Search
EGFR Lung Cancer Resisters
Menu
  • HOME
  • WHO WE ARE
    • LEADERSHIP
    • OUR MISSION
    • EXPERT PARTNERSHIPS
    • YOUNG INVESTIGATORS
    • MEMBERSHIP
    • JOIN
  • PROJECTS & EDUCATION
    • EGFR RESISTERS PATIENT & CAREGIVER SUMMIT
    • WHEN EGFR+ LUNG CANCER SPREADS TO THE BRAIN
    • ABOUT EGFR
    • PROJECT PRIORITY
    • ANNUAL RESEARCH SUMMIT
    • RESEARCH AWARDS
    • EDUCATION
  • NEWS
    • ALL NEWS
    • ADVOCACY
    • COPING & STORIES
    • RESEARCH & TREATMENT
  • SOCIAL MEDIA
    • INSTAGRAM
    • FACEBOOK
    • X
    • OUR YouTube CHANNEL
  • ALLIANCES & RESOURCES
    • MONTHLY NEWSLETTERS
    • LUNG CANCER ADVOCACY
    • BIOMARKER GROUPS
    • CONTACT US
  • SUPPORT
  • DONATE
    ResearchTreatments

    Current Treatment Landscape for EGFR-Mutated NSCLC

    By laurabbook@gmail.comNo Comments

    *October 2023*

    Sandip P. Patel, MD discusses treatment options available for patients with EGFR-mutant NSCLC who progress on  EGFR TKIs and platinum-based chemotherapy.

    Watch video here.

     

    GIVE TODAY

    DONATE

    Categories

    • Advocacy 49
    • Coping With Cancer 58
    • EGFR Resisters Announcements/Updates 5
    • Funding 14
    • Partners 2
    • Research 526
    • Resources 2
    • Stories 26
    • Treatments 502

    STAY CONNECTED

    VIEW NEWSLETTERS

    You Might Like

    • FDA Food and Drug Admin Logo
      FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics July 3, 2022
    • Future Medicine
      Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer July 3, 2022
    • ASCO Educational Book logo
      Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It? July 3, 2022
    • Nature Magazine
      Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management July 3, 2022
    • frontiers in oncology logo
      Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report July 3, 2022

    BECOME A MEMBER

    JOIN
    Share
    Share Share Share Pin

    The EGFR Resisters is a global community of patients and caregivers impacted by EGFR-positive lung cancer. We’re here to share knowledge, offer support and collaborate to drive progress in research and care. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.

    Medical Disclaimer
    Policies

    WHO WE ARE

    • Leadership
    • Our Mission
    • Expert Partnerships
    • Young Investigators
    • Membership
    • Support
    • Donate

    PROJECTS

    • About EGFR
    • Patient & Caregiver Summit
    • Project Priority
    • Annual Research Summit
    • Research Awards
    • Education

    ALLIANCES & RESOURCES

    • Monthly Newsletters
    • Lung Cancer Advocacy
    • Biomarker Groups
    • Contact Us

    © 2025 EGFR Lung Cancer Resisters. Built by Reinhardt Designs.

    • twitter
    • facebook
    • youtube
    • instagram
    • email
    Close Menu
    • HOME
    • WHO WE ARE
      • LEADERSHIP
      • OUR MISSION
      • EXPERT PARTNERSHIPS
      • YOUNG INVESTIGATORS
      • MEMBERSHIP
      • JOIN
    • PROJECTS & EDUCATION
      • EGFR RESISTERS PATIENT & CAREGIVER SUMMIT
      • WHEN EGFR+ LUNG CANCER SPREADS TO THE BRAIN
      • ABOUT EGFR
      • PROJECT PRIORITY
      • ANNUAL RESEARCH SUMMIT
      • RESEARCH AWARDS
      • EDUCATION
    • NEWS
      • ALL NEWS
      • ADVOCACY
      • COPING & STORIES
      • RESEARCH & TREATMENT
    • SOCIAL MEDIA
      • INSTAGRAM
      • FACEBOOK
      • X
      • OUR YouTube CHANNEL
    • ALLIANCES & RESOURCES
      • MONTHLY NEWSLETTERS
      • LUNG CANCER ADVOCACY
      • BIOMARKER GROUPS
      • CONTACT US
    • SUPPORT
    • DONATE
    • x-twitter
    • facebook
    • youtube
    • instagram
    EGFR Lung Cancer Resisters
    Manage Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}